JD419, a Staphylococcus aureus Phage With a Unique Morphology and Broad Host Range

Phage therapy represents a possible treatment option to cure infections caused by multidrug-resistant bacteria, including methicillin and vancomycin-resistant Staphylococcus aureus, to which most antibiotics have become ineffective. In the present study, we report the isolation and complete characterization of a novel phage named JD219 exhibiting a broad host range able to infect 61 of 138 clinical strains of S. aureus tested, which included MRSA strains as well. The phage JD419 exhibits a unique morphology with an elongated capsid and a flexible tail. To evaluate the potential of JD419 to be used as a therapeutic phage, we tested the ability of the phage particles to remain infectious after treatment exceeding physiological pH or temperature. The activity was retained at pH values of 6.0–8.0 and below 50°C. As phages can contain virulence genes, JD419’s complete genome was sequenced. The 45509 bp genome is predicted to contain 65 ORFs, none of which show homology to any known virulence or antibiotic resistance genes. Genome analysis indicates that JD419 is a temperate phage, despite observing rapid replication and lysis of host strains. Following the recent advances in synthetic biology, JD419 can be modified by gene engineering to remove prophage-related genes, preventing potential lysogeny, in order to be deployed as a therapeutic phage.

[1]  S. Leptihn,et al.  Encapsulation and Delivery of Therapeutic Phages , 2020, Applied and Environmental Microbiology.

[2]  S. Leptihn,et al.  A Biological Inventory of Prophages in A. baumannii Genomes Reveal Distinct Distributions in Classes, Length, and Genomic Positions , 2020, Frontiers in Microbiology.

[3]  E. Ilina,et al.  Contribution of Podoviridae and Myoviridae bacteriophages to the effectiveness of anti-staphylococcal therapeutic cocktails , 2020, Scientific Reports.

[4]  S. Leptihn,et al.  Secondary Bacterial Infections in Patients With Viral Pneumonia , 2020, Frontiers in Medicine.

[5]  S. Leptihn,et al.  Secondary Bacterial Infections During Pulmonary Viral Disease: Phage Therapeutics as Alternatives to Antibiotics? , 2020, Frontiers in Microbiology.

[6]  P. He,et al.  Identification of a novel phage targeting methicillin-resistant Staphylococcus aureus In vitro and In vivo. , 2020, Microbial pathogenesis.

[7]  S. Leptihn.  Welcome Back to the Pre-Penicillin Era. Why We Desperately Need New Strategies in the Battle Against Bacterial Pathogens , 2019 .

[8]  Tingting Feng,et al.  Exploring the whole standard operating procedure for phage therapy in clinical practice , 2019, Journal of Translational Medicine.

[9]  J. Iredell,et al.  Bacteriophage Therapy of Ventilator-associated Pneumonia and Empyema caused by Pseudomonas aeruginosa. , 2019, American journal of respiratory and critical care medicine.

[10]  C. Wolz,et al.  Temperate Phages of Staphylococcus aureus , 2019, Microbiology spectrum.

[11]  R. Schooley,et al.  Engineered bacteriophages for treatment of a patient with a disseminated drug resistant Mycobacterium abscessus , 2019, Nature Medicine.

[12]  A. R. Costa,et al.  Phage Therapy: Going Temperate? , 2019, Trends in microbiology.

[13]  S. Bari,et al.  Draft Genome Sequences of Staphylococcus Podophages JBug18, Pike, Pontiff, and Pabna , 2019, Microbiology Resource Announcements.

[14]  S. Sarker,et al.  Metagenome analysis of Russian and Georgian Pyophage cocktails and a placebo‐controlled safety trial of single phage versus phage cocktail in healthy Staphylococcus aureus carriers , 2018, Environmental microbiology.

[15]  K. Dong,et al.  Prevention of Dermal Abscess Formation Caused by Staphylococcus aureus Using Phage JD007 in Nude Mice , 2018, Front. Microbiol..

[16]  Y. Tanji,et al.  Bacteriophage ΦSA012 Has a Broad Host Range against Staphylococcus aureus and Effective Lytic Capacity in a Mouse Mastitis Model , 2018, Biology.

[17]  Forest Rohwer,et al.  Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection , 2017, Antimicrobial Agents and Chemotherapy.

[18]  K. Dong,et al.  Characterization and complete genome of the virulent Myoviridae phage JD007 active against a variety of Staphylococcus aureus isolates from different hospitals in Shanghai, China , 2017, Virology Journal.

[19]  K. Dong,et al.  Safety assessment of Staphylococcus phages of the family Myoviridae based on complete genome sequences , 2017, Scientific Reports.

[20]  A. Górski,et al.  Facing Antibiotic Resistance: Staphylococcus aureus Phages as a Medical Tool , 2014, Viruses.

[21]  B. Limbago,et al.  Report of the 13th Vancomycin-Resistant Staphylococcus aureus Isolate from the United States , 2013, Journal of Clinical Microbiology.

[22]  B. Bao,et al.  Momordica charantia (Bitter Melon) Reduces Obesity-Associated Macrophage and Mast Cell Infiltration as well as Inflammatory Cytokine Expression in Adipose Tissues , 2013, PloS one.

[23]  Y. Tong,et al.  Characterization of Enterococcus faecalis Phage IME-EF1 and Its Endolysin , 2013, PloS one.

[24]  Hyunjin Yoon,et al.  Genomic Investigation of Lysogen Formation and Host Lysis Systems of the Salmonella Temperate Bacteriophage SPN9CC , 2013, Applied and Environmental Microbiology.

[25]  M. Loessner,et al.  Bacteriophage P70: Unique Morphology and Unrelatedness to Other Listeria Bacteriophages , 2012, Journal of Virology.

[26]  You-Hee Cho,et al.  Antibacterial Efficacy of Temperate Phage-Mediated Inhibition of Bacterial Group Motilities , 2012, Antimicrobial Agents and Chemotherapy.

[27]  Robert A. Edwards,et al.  PHACTS, a computational approach to classifying the lifestyle of phages , 2012, Bioinform..

[28]  S. M. Kim,et al.  Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin , 2011, Biofouling.

[29]  S. Abedon,et al.  Phage treatment of human infections , 2011, Bacteriophage.

[30]  N. Perna,et al.  progressiveMauve: Multiple Genome Alignment with Gene Gain, Loss and Rearrangement , 2010, PloS one.

[31]  C. Wolz,et al.  Diversity of Prophages in Dominant Staphylococcus aureus Clonal Lineages , 2009, Journal of bacteriology.

[32]  Mihai Pop,et al.  ARDB—Antibiotic Resistance Genes Database , 2008, Nucleic Acids Res..

[33]  Rick L. Stevens,et al.  The RAST Server: Rapid Annotations using Subsystems Technology , 2008, BMC Genomics.

[34]  Mark Borodovsky,et al.  GeneMark: web software for gene finding in prokaryotes, eukaryotes and viruses , 2005, Nucleic Acids Res..

[35]  S. Salzberg,et al.  Improved microbial gene identification with GLIMMER. , 1999, Nucleic acids research.

[36]  S. Eddy,et al.  tRNAscan-SE: a program for improved detection of transfer RNA genes in genomic sequence. , 1997, Nucleic acids research.

[37]  L. Shapiro,et al.  Structural studies on the capsid of Caulobacter crescentus bacteriophage phiCbK. , 1972, Journal of molecular biology.

[38]  R. Moellering.  MRSA: the first half century. , 2012, The Journal of antimicrobial chemotherapy.

[39]  J. Gawor,et al.  Genomics of staphylococcal Twort-like phages--potential therapeutics of the post-antibiotic era. , 2012, Advances in virus research.

[40]  D. Carlton,et al.  Antibacterial Efficacy , 2022 .